The FDA will consider the companion diagnostic application alongside data for Pfizer's talazoparib in BRCA-mutated advanced breast cancer.
The funding will be available to members of the Association of Community Cancer Centers, a cancer care provider advocacy group.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Under the agreement, new companion diagnostics will be included in updates to FoundationOne CDx, which was recently FDA approved.
Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The companies will use Berkeley Lights' technology to improve Pfizer's monoclonal antibody discovery and gene editing workflows.
The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.